BCL2 mutations have been suggested to confer an adverse prognosis to follicular lymphoma (FL) patients, but their prognostic value has not been assessed in patients treated with a rituximabcontaining regimen. Here we evaluated the prognostic value of BCL2 mutations in a large prospective cohort of 252 patients with FL treated with immunochemotherapy in the PRIMA randomized trial. Using a DNA-targeted sequencing approach, we detected amino acid altering mutations in 135 patients (54%) and showed that these mutations were probably mediated by the overactivation of AICDA (activation-induced cytidine deaminase) in the context of the t(14;18) translocation. The BCL2 variants identified in PRIMA patients affected the BH1, BH2, and BH3 functional motifs at a lower frequency than the N-terminus and flexible loop domain, with mostly conservative aminoacid changes. With a median follow-up of 6.7 years, we did not observe any impact of BCL2 mutations either on overall survival or progression-free survival.
| I N T R O D U C T I O N
The clinical course of follicular lymphoma (FL) is heterogeneous, and the best clinical predictor of outcome is the FLIPI score. 1, 2 It is increasingly recognized that genomic alterations can influence patients' outcome, which led recently to the integration of genes mutational status in the prognostic stratification of patients with FL. 3 The t(14;18) translocation is the hallmark of FL, resulting in overexpression of the BCL2 oncogene. BCL2 is also frequently mutated in FL, 4 and BCL2 mutations were recently shown to be associated with an increased risk of transformation and risk of death due to lymphoma. 5 Mutation analysis in the Correia's retrospective study used Sanger sequencing in a patient cohort mostly treated in the absence of rituximab. Here, we use next-generation sequencing to identify BCL2 mutations and assess their prognostic value in a large prospective cohort of 252 patients with FL treated in the PRIMA Phase III trial that evaluated Rituximab maintenance after immunochemotherapy as first-line treatment in FL. 6 
| M E T H O D S
This study was conducted in accordance with the Declaration of Helsinki. All patients signed a consent form for participation in specific biological studies.
Tumor biopsy specimens were obtained at FL diagnosis from 252 high tumor burden patients included in the PRIMA trial. 6 DNA was extracted from FFPE tissues (n 5 98) or fresh-frozen tissues (FF, n 5 154). A DNA-targeted sequencing approach using the FoundationOne Heme platform was performed as described previously 7 (mean coverage 7973). Lymphoma-specific variants identified in the BCL2 gene were filtered to remove known polymorphisms (dbSNP database v137) and possible sequencing artefacts by exclusion of variants with variant allele frequency (VAF) under 5% (n 5 18). These data also provided information on IGH-BCL2 rearrangement.
RNA-seq data available for 143 of the 252 patients was used to assess expression levels of AICDA transcript.
The correlation between BCL2 mutation status and clinical or biological characteristics were assessed using Fisher's exact test. Differential expression levels or VAF were compared using the Mann-Whitney test. Progression-free survival (PFS) and overall survival (OS), defined by international criteria, 8 were estimated by the Kaplan-Meier product limit method and compared by log-rank test.
| R E S U L T S AN D D I S C U S S I O N
One hundred and thirty-five patients (54%) harbored at least one amino acid altering mutation, consisting in single nucleotide variations (SNVs) (n 5 294) or small in-frame insertions (n 5 3) (Supporting Information Table 1 ). This proportion was slightly higher in fresh frozen tis- Information Table 2 ). Mutations in the BH3-binding groove of BCL-2 were largely conservative in nature and not expected to affect binding to pro-apoptotic proteins based on structural analysis of the BCL-2 protein bound to the BAX BH3 peptide (Supporting Information Figure 1 ). This is in agreement with computational analysis suggesting that none of the mutations observed in BCL-2 are predicted to have deleterious effects (MutationAssessor 11, 12 ) (Supporting Information Table 3 ). However, further in vitro functional studies and clinical results from BCL-2 inhibitors' trials will warrant the functional consequences of these mutations.
Variant Allele Frequency (VAF) depends on the sample's tumor content, the hetero-or homozygous status, the copy number variation of the considered locus, and the clonal or subclonal nature of the mutation. The VAF of BCL2 mutations were highly heterogeneous (range:
0.06-0.59; median: 0.26) in our cohort. By studying the VAF ratio (defined as the ratio of the VAF compared to the higher BCL2 mutation VAF of the same sample) in 71 patients carrying multiple BCL2 mutations, we identified 29% of the mutations with a low VAF ratio.
Although tumor cell content may also account for this variability, these results indicate that most BCL2 mutations accumulate in subclones, reflecting ongoing genomic instability in FL ( Figure 1B) . 13 An IGH-BCL2 rearrangement was identified in 92% (141/154) and 42% (41/98) of the FF and FFPE samples, respectively, which led us to limit the following analysis on the subgroup of FF samples. The presence of mutations in the BCL2 sequence was associated with the presence of IGH-BCL2 rearrangements ( Figure 1C) , as previously reported, 14, 15 suggesting that BCL2 mutations might be a consequence of the juxtaposition of the BCL2 gene in the vicinity of the IGH locus caused by the t(14;18) translocation. The activation of activationinduced cytidine deaminase (AICDA) might also account for a higher frequency of BCL2 mutations. 5, 15 Indeed, our RNAseq data revealed a slightly higher expression of AICDA mRNA in BCL2 mutated compared to wild-type samples (P 5 .003) ( Figure 1D ). Moreover, 51% of the SNVs were transitions (C to T or G to A) and 24% occurred at preferred AICDA target sequences RGYW/WRCY.
Finally, we found no association between any of the clinical characteristics at diagnosis and BCL2 mutation status (Supporting Information Table 4 ). With a median follow-up of 6.7 years, we were unable to detect any significant difference in PFS or OS between mutated and wild-type patients (Figure 2A ; the lack of survival effect was maintained even when only mutations common to both studies were analyzed (not shown). Patients from both studies were treated with chemotherapy, where BCL2 mutations may contribute to resistance to therapy. 16, 17 On the contrary, all PRIMA patients were treated with a rituximab-based regimen, and one possible interpretation is that the addition of rituximab could explain the improvement in outcome of BCL2 mutated patients. Indeed, rituximab is mainly acting through complement dependent cytotoxicity and 
